Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
News and updates about STERIS plc (NYSE: STE) focus on its role as a medical technology company that supports patient care with an emphasis on infection prevention. The company regularly issues press releases from Dublin, Ireland, describing its financial performance, dividends, leadership changes and investor events, giving readers insight into how its healthcare and life science products and services business is developing.
Investors following STERIS news can expect recurring coverage of quarterly and annual financial results, where the company reports total revenue from continuing operations, segment performance for Healthcare, Applied Sterilization Technologies (AST) and Life Sciences, and both GAAP and non-GAAP metrics such as adjusted earnings per diluted share and free cash flow. These releases often include management commentary and an outlook for future fiscal periods, along with detailed explanations of non-GAAP measures.
STERIS news also includes announcements of quarterly dividends, with information on dividend amounts, payment dates and record dates. Some releases highlight the company’s history of dividend growth. Governance and leadership developments, such as transitions in the Chief Financial Officer role or changes to the Board of Directors, are disclosed through both press releases and related SEC filings, and are frequently summarized in the news flow.
In addition, STERIS routinely announces conference calls to discuss financial results, providing access details and replay information for investors and analysts. Each release typically contains a cautionary statement regarding forward-looking information and references to risk factors described in the company’s SEC filings. Readers who monitor this news stream can follow how STERIS communicates its financial performance, strategic outlook, shareholder returns and governance matters over time.
STERIS (NYSE: STE) has scheduled a conference call to discuss its fiscal 2026 first quarter results on August 7, 2025, at 9:00 a.m. ET. The company will release its financial results after market close on August 6, 2025.
Investors can access the call through www.steris-ir.com or by phone using specific dial-in numbers for U.S. (1-833-535-2199) and international (1-412-902-6776) participants. A replay will be available from 12:00 p.m. ET on August 7, using access code 2889488.
STERIS (NYSE: STE) reported strong financial results for fiscal 2025, with full-year revenue from continuing operations increasing 6% to $5.5 billion. The company's fourth quarter revenue grew 4% to $1.5 billion, with constant currency organic revenue growth of 6%. Full-year net income reached $610.1 million, or $6.16 per diluted share, while adjusted EPS increased to $9.22.
Healthcare segment revenue grew 5% to $1.1 billion in Q4, while Applied Sterilization Technologies (AST) revenue increased 9% to $273.9 million. Life Sciences revenue decreased 7% to $149.5 million. The company generated strong free cash flow of $787.2 million for fiscal 2025.
For fiscal 2026, STERIS expects 6-7% revenue growth and adjusted EPS of $9.90-$10.15, despite an estimated $30 million negative impact from tariffs.
STERIS (NYSE: STE) has announced it will host a conference call on May 15, 2025 at 9:00 a.m. ET to discuss its fiscal 2025 fourth quarter and full year financial results. The company will release its financial results press release after market close on May 14, 2025.
Investors can access the live call through www.steris-ir.com or by phone using 1-833-535-2199 (US) or 1-412-902-6776 (International). A replay will be available from 12:00 p.m. ET on May 15, using access code 5194825, via the company website or by calling 1-877-344-7529 (US) or 1-412-317-0088 (International).
STERIS (NYSE: STE) reported strong financial results for Q3 FY2025. Total revenue from continuing operations increased 6% to $1.4 billion, with constant currency organic revenue also growing 6%. Net income reached $173.6 million ($1.75 per diluted share), up from $148.4 million in Q3 FY2024. Adjusted net income was $229.1 million ($2.32 per diluted share).
Healthcare revenue grew 7% to $976.0 million, while Applied Sterilization Technologies revenue increased 10% to $258.1 million. Life Sciences revenue decreased 7% to $136.4 million. Free cash flow for the first nine months reached $588.1 million, up from $457.0 million.
The company updated its FY2025 outlook, now expecting revenue growth of approximately 6%, down from previous guidance of 6.5-7.5%, primarily due to currency impacts and lower Healthcare capital equipment revenue. Adjusted EPS guidance was revised to $9.05-$9.15.
STERIS plc (NYSE: STE) has announced a quarterly interim dividend of $0.57 per share. The dividend will be paid on March 21, 2025, to shareholders who are on record at the close of business on February 20, 2025.
STERIS, a leading global provider of products and services focused on infection prevention, supports patient care and helps customers create a healthier and safer world through innovative healthcare and life sciences solutions globally.
STERIS (NYSE: STE) has announced it will host a conference call on February 6, 2025, at 9:00 a.m. ET to discuss its fiscal 2025 third quarter financial results. The company will release its financial results press release after U.S. market closure on February 5, 2025.
Investors can access the live conference call through www.steris-ir.com or by phone using 1-833-535-2199 (U.S.) or 1-412-902-6776 (International). A replay will be available from 12:00 p.m. ET on February 6, using access code 2513153, accessible via the company website or by calling 1-877-344-7529 (U.S.) or 1-412-317-0088 (International).
STERIS plc (NYSE: STE) announced that a jury trial against its subsidiary Isomedix Operations ended in a mistrial on January 17, 2025. The trial, which began on December 4, 2024, involved claims that ethylene oxide emissions from a Waukegan, Illinois sterilization facility caused personal injury. Isomedix operated the facility from 2005 to 2008.
The mistrial was declared at the plaintiff's request during jury deliberations when the dismissal of a juror reduced the jury count below twelve. The case, pending in the Circuit Court of Cook County, Illinois, will be scheduled for re-trial. Isomedix maintains its commitment to defending against allegations regarding its ethylene oxide operations and emissions, stating it has invested in facilities and implemented processes that meet or exceed environmental regulatory standards.
STERIS reported strong fiscal 2025 second quarter results with total revenue increasing 7% to $1.3 billion. Net income reached $150.2 million ($1.51 per share), up from $119.8 million in the previous year. Healthcare revenue grew 9% to $944.2 million, while Applied Sterilization Technologies revenue increased 9% to $256.7 million. Life Sciences revenue decreased 4% to $127.9 million. The company maintained its fiscal 2025 outlook, expecting 6.5-7.5% revenue growth and adjusted earnings per share of $9.05-$9.25.
STERIS (NYSE: STE) has announced a quarterly interim dividend of $0.57 per share, payable on December 19, 2024. Shareholders of record at the close of business on November 19, 2024 will be eligible for this distribution. The company, a global leader in infection prevention products and services for healthcare and life sciences, provides additional information about U.S. tax treatment of dividends on their investor relations website.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
